Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12339960 | 0.95 | HDAC1 (0.52) | MAOBKLKB1KDM5BHDAC1HDAC8 | |
| SCHEMBL12339937 | 0.93 | HDAC1 (0.50) | MAOBKLKB1KDM5BHDAC1HDAC8 | |
| SCHEMBL12339963 | 0.86 | TUBB4A (0.57) | MAOBKLKB1KDM5B | |
| SCHEMBL12339950 | 0.85 | HDAC1 (0.49) | MAOBKLKB1HDAC1HDAC8HDAC6 | |
| SCHEMBL12902828 | 0.85 | MAOB (0.48) | MAOBKLKB1HDAC1HDAC8HDAC6 | |
| SCHEMBL12339928 | 0.83 | TUBB4A (0.54) | MAOBKLKB1KDM5B | |
| SCHEMBL13819976 | 0.83 | ANPEP (0.54) | HDAC1HDAC8HDAC6 | |
| SCHEMBL12339961 | 0.81 | TUBB4A (0.44) | MAOBKDM5BHDAC1HDAC8HDAC6 | |
| SCHEMBL12339962 | 0.80 | HDAC1 (0.48) | HDAC1HDAC8HDAC6 | |
| SCHEMBL12339959 | 0.80 | TUBB4A (0.51) | MAOBKLKB1KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729270-B2 | Anti-cancer compounds, synthesis thereof, and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729270-B2 | Anti-cancer compounds, synthesis thereof, and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | MCL1, BRDT, GLS | MAOB 1529/4885KLKB1 2046/4885KDM5B 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.